INBX
Inhibrx Biosciences, Inc.NASDAQHealthcare$63.53-5.25%ClosedMarket Cap: $928.0M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
123.46
P/S
715.97
EV/EBITDA
-7.21
DCF Value
$0.61
FCF Yield
-13.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-91.0%
Operating Margin
-10386.5%
Net Margin
-10773.5%
ROE
-269.6%
ROA
-95.6%
ROIC
-117.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-30.9M | $-32.8M | $-2.11 | — |
| FY 2025 | $1.3M | -91.0% | $-135.0M | $-140.1M | $-9.04 | — |
| Q3 2025 | $0.00 | -Infinity% | $-33.8M | $-35.3M | $-2.28 | — |
| Q2 2025 | $1.3M | 49.1% | $-27.4M | $-28.7M | $-1.85 | — |
| Q1 2025 | $0.00 | -Infinity% | $-42.9M | $-43.3M | $-2.80 | — |
| Q4 2024 | $100.0K | -589.0% | $-49.9M | $-47.9M | $-3.31 | — |
| FY 2024 | $200.0K | -1042.5% | $-331.4M | $1.69B | $116.58 | $0.85 |
| Q3 2024 | $0.00 | -Infinity% | $-46.8M | $-43.9M | $-2.84 | — |
| Q2 2024 | $100.0K | 100.0% | $-160.9M | $1.86B | $125.48 | $0.85 |
| Q1 2024 | $0.00 | -Infinity% | $-73.8M | $-78.7M | $-1.44 | — |
| Q4 2023 | $1.6M | 81.8% | $-88.3M | $-93.6M | $-1.73 | — |
| FY 2023 | $1.8M | 33.8% | $-219.2M | $-241.4M | $-5.12 | — |